Immunovant, Inc.
IMVT · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $114 | $101 | $94 | $95 |
| G&A Expenses | $18 | $26 | $20 | $20 |
| SG&A Expenses | $18 | $26 | $20 | $20 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $132 | $127 | $114 | $114 |
| Operating Income | -$132 | -$127 | -$114 | -$114 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $6 | $8 | $8 | $3 |
| Pre-Tax Income | -$126 | -$120 | -$106 | -$111 |
| Tax Expense | $1 | $1 | $1 | $0 |
| Net Income | -$127 | -$121 | -$106 | -$111 |
| % Margin | – | – | – | – |
| EPS | -0.73 | -0.71 | -0.64 | -0.76 |
| % Growth | -2.8% | -10.9% | 15.8% | – |
| EPS Diluted | -0.73 | -0.71 | -0.64 | -0.76 |
| Weighted Avg Shares Out | 174 | 171 | 152 | 147 |
| Weighted Avg Shares Out Dil | 174 | 171 | 152 | 147 |
| Supplemental Information | – | – | – | – |
| Interest Income | $6 | $6 | $7 | $5 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$132 | -$127 | -$114 | -$114 |
| % Margin | – | – | – | – |